Last reviewed · How we verify
Obesity pharmacotherapy
Obesity pharmacotherapy refers to a class of medications that reduce appetite, increase satiety, or enhance metabolic rate to promote weight loss.
Obesity pharmacotherapy represents a class of medications used to treat obesity and weight management, with Denver Health and Hospital Authority involved in clinical evaluation. The field encompasses multiple mechanistic approaches including GLP-1 receptor agonists (semaglutide), dual GIP/GLP-1 receptor agonists (tirzepatide), SGLT2 inhibitors (dapagliflozin), and investigational agents like nimacimab. Clinical development spans 50 trials across Phase 1–4 and observational studies, with active recruitment in post-smoking cessation weight management, binge eating disorder, and metabolic surgery optimization. The obesity pharmacotherapy market is experiencing rapid expansion driven by efficacy data and growing recognition of obesity as a chronic disease, with GLP-1 agonists achieving blockbuster status (semaglutide/Ozempic generating >$5B annually). Pipeline expansion includes combination therapies (tirzepatide + cognitive behavioral therapy), novel targets (brain plasticity modulation), and indication expansion into alcohol use disorder and endometrial cancer risk reduction.
At a glance
| Generic name | Obesity pharmacotherapy |
|---|---|
| Also known as | Phentermine or phentermine-topiramate (Qsymia) |
| Sponsor | Denver Health and Hospital Authority |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Metabolic Disease |
| Phase | FDA-approved |
Mechanism of action
This is a broad category encompassing multiple drug classes with different mechanisms, including GLP-1 receptor agonists (which slow gastric emptying and reduce hunger signals), lipase inhibitors (which reduce dietary fat absorption), and sympathomimetic amines (which increase energy expenditure). The specific mechanism depends on which agent is being used within the obesity pharmacotherapy portfolio.
Approved indications
- Obesity management
- Weight reduction in patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Headache
- Fatigue
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Obesity pharmacotherapy CI brief — competitive landscape report
- Obesity pharmacotherapy updates RSS · CI watch RSS
- Denver Health and Hospital Authority portfolio CI